433-06-7

Basic information

• Product Name: 2,2,2-TRIFLUOROETHYL P-TOLUENESULFONATE
• Synonyms: P-TOLUENESULFONIC ACID 2,2,2-TRIFLUOROETHYL ESTER;TRIFLUORETHYLTOSYLATE;TRIFLUOROETHANOL TOSYLATE;2,2,2-TRIFLUOROETHYL P-TOLUENESULF;2,2,2-trifluoroethyl ester;2,2,2-trifluoro-, p-toluenesulfonate;o-(p-tosyl)a,a,a,-trifluoroethanol;2,2,2-Trifluoroethyl 4-methylbenzenesulphonate, 2,2,2-Trifluoroethyl tosylate
• CAS NO: 433-06-7
• Molecular Formula: C₉H₉F₃O₃S
• Molecular Weight: 254.23
• EINECS: 207-085-5
• Product Categories: blocks;BuildingBlocks;FluoroCompounds;API intermediates;Fluorinated Building Blocks;Fluorinating Reagents & Building Blocks for Fluorinated Biochemical Compounds;Synthetic Organic Chemistry;Organic Building Blocks;Sulfur Compounds;Tosylates
• Mol File: 433-06-7.mol

Chemical Properties

• Melting Point: 36-38 °C(lit.)
• Boiling Point: 87-92 °C0.1 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: White crystalline solid
• Density: 1 g/cm3
• Vapor Pressure: 0.00418mmHg at 25°C
• Refractive Index: 1.521
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: Chloroform (Sparingly), Methanol (Sparingly)
• Sensitive: Moisture Sensitive
• BRN: 2699394
• CAS DataBase Reference: 2,2,2-TRIFLUOROETHYL P-TOLUENESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2,2-TRIFLUOROETHYL P-TOLUENESULFONATE(433-06-7)
• EPA Substance Registry System: 2,2,2-TRIFLUOROETHYL P-TOLUENESULFONATE(433-06-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• TSCA: T
• HazardClass: IRRITANT
• Hazardous Substances Data: 433-06-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,2,2-Trifluoroethyl p-toluenesulfonate is used as a trifluoroethylation agent for the preparation of 2,2,2-trifluoroethyl phenyl sulfone, a potential 2,2,2-trifluoroethyl pronucleophile. This application is significant in the synthesis of various pharmaceutical compounds, as the trifluoroethyl group can enhance the biological activity and pharmacokinetic properties of the resulting molecules.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2,2,2-Trifluoroethyl p-toluenesulfonate is utilized as a reagent to introduce the trifluoroethyl group into various organic compounds. This modification can improve the stability, reactivity, and overall performance of the synthesized products, making it a valuable tool for chemists in developing new materials and compounds.
Used in Material Science:
2,2,2-Trifluoroethyl p-toluenesulfonate can also be employed in the development of novel materials with enhanced properties. The introduction of the trifluoroethyl group can lead to materials with improved thermal stability, chemical resistance, and other desirable characteristics, making it a useful component in the advancement of material science.

InChI:InChI=1/C7H8FNO2S/c1-9-12(10,11)7-4-2-6(8)3-5-7/h2-5,9H,1H3

Upstream product

• 75-89-8 2,2,2-trifluoroethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 288-32-4 1H-imidazole 
• 25370-91-6 N-benzyl-N'-(4-toluenesulfonyloxy)diimide N-oxide 
• 371-67-5 2,2,2-trifluorodiazoethane 
• 104-15-4 toluene-4-sulfonic acid 
• 83-72-7 2-hydroxynaphtho-1,4-quinone 
• 166903-46-4 1-[hydroxy(tosyloxy)iodo]-1H,1H-perfluoroethane 
• 824-79-3 sodium 4-methylbenzenesulfinate 
• 4703-22-4 N-tosylpiperidine 
• 17721-45-8 1-tosylazepane 

Downstream Products

• 811-97-2 1,1,1,2-tetrafluoroethane 
• 353-83-3 1,1,1-trifluoro-2-iodoethane 
• 70159-42-1 Cyclohexylidene-(toluene-4-sulfonyloxy)-acetic acid 
• 70159-45-4 α-(toluene-4-sulfonyloxy)-trans-cinnamic acid 
• 70159-41-0 3-Methyl-2-(toluene-4-sulfonyloxy)-but-2-enoic acid 
• 143264-59-9 1-(1-Difluoromethylene-pentyl)-4-nitro-benzene 
• 143264-65-7 (1-Difluoromethylene-2-methyl-butyl)-benzene 
• 143264-58-8 1,1-Difluoro-2-phenyl-1-hexene 
• 62158-91-2 (2,2,2-trifluoroethyl) (4-fluorophenyl) sulfide 
• 130612-75-8 (2,2,2-trifluoroethyl) (4-methoxyphenyl) sulfide 
• 143264-61-3 1-[4-(1-Difluoromethylene-pentyl)-phenyl]-ethanone 
• 149989-04-8 1-(1-Difluoromethylene-pentyl)-4-methyl-benzene 
• 143264-64-6 1-(1-Difluoromethylene-pentyl)-4-methoxy-benzene 
• 134810-59-6 o-(1,1-difluorohex-1-en-2-yl)aniline 

Relevant articles and documents

Synthesis of new fluorinated imidazolium ionic liquids and their prospective function as the electrolytes for lithium-ion batteries

Two fluorine-containing ionic liquids, 1-(2,2,2-trifluoroethyl)-3- methylimidazolium tosylate and 1-(2,2,2-trifluoroethyl)-3-methylimidazolium bis(trifluoromethanesulfonyl)imide (TFSI anion), were obtained in good yields and high purity via a green pathway procedure free of solvent and hazardous catalyst. The incorporation of CF3 moieties in imidazolium structure decreases the ILs TFSI melting point. The preliminary electrochemical results are very promising, a wide electrochemical stability up to 5.7 V vs Li +/Li for the fluorinated imidazolium with TFSI anion.

Exploring Electrochemical C(sp3)-H Oxidation for the Late-Stage Methylation of Complex Molecules

The magic methyl effect, a dramatic boost in the potency of biologically active compounds from the incorporation of a single methyl group, provides a simple yet powerful strategy employed by medicinal chemists in the drug discovery process. Despite significant advances, methodologies that enable the selective C(sp3)-H methylation of structurally complex medicinal agents remain very limited. In this work, we disclose a modular, efficient, and selective strategy for the α-methylation of protected amines (i.e., amides, carbamates, and sulfonamides) by means of electrochemical oxidation. Mechanistic analysis guided our development of an improved electrochemical protocol on the basis of the classic Shono oxidation reaction, which features broad reaction scope, high functional group compatibility, and operational simplicity. Importantly, this reaction system is amenable to the late-stage functionalization of complex targets containing basic nitrogen groups that are prevalent in medicinally active agents. When combined with organozinc-mediated C-C bond formation, our protocol enabled the direct methylation of a myriad of amine derivatives including those that have previously been explored for the magic methyl effect. This synthesis strategy thus circumvents multistep de novo synthesis that is currently necessary to access such compounds and has the potential to accelerate drug discovery efforts.

KIF18A INHIBITORS

Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

PYRIDINE DERIVATIVES AS KIF18A INHIBITORS

Amide compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

Palladium-Catalyzed Fluoroarylation of gem-Difluoroenynes to Access Trisubstituted Trifluoromethyl Allenes

Various new transformations of gem-difluoroalkenes leading to trifluoromethyl substituted compounds have been well established in the past years. However, the development of new transformations of gem-difluoroenynes lags much behind. Herein is reported the fluoroarylation of 1,1-difluoro-1,3-enynes with aryl halides in the presence of silver fluoride affording trisubstituted trifluoromethyl allenes under the catalysis of palladium. The reaction features mild conditions, high functional-group tolerance, and high regioselectivity.

METHOD FOR PRODUCING MERCAPTOPHENOL COMPOUND AND INTERMEDIATE OF SAID COMPOUND

A production method in which a mercaptophenol compound is obtained using an industrially preferred sulfur atom introduction reaction, and intermediate compounds of the mercaptophenol compound are provided. A method for producing a mercaptophenol compound in which a phenyl carbamate compound is produced using a phenol compound as a raw material, and then a sulfur atom is regioselectively introduced by a reaction with sulfur monochloride, and a phenyl mercaptocarbamate compound is produced as an intermediate.

QUINAZOLINE DERIVATIVE AND USE THEREOF

The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as Pan-HER tyrosine kinase inhibitors.

Method for preparing hydrofluoroether through two-step process

The invention discloses a method for preparing hydrofluoroether through a two-step process. With the method provided by the invention, p-toluensulfonyl chloride and fluorine-containing alcohol are subjected to a reaction to obtain p-toluenesulfonate, and the p-toluenesulfonate and sodium alkoxide are subjected to a Williamson ether synthetic reaction to obtain the hydrofluoroether. The method disclosed by the invention has the advantages of cheap and low-toxicity raw materials, mild and controllable reaction conditions, and high yield.

Peptidylarginine deiminase inhibitor and application thereof

The invention belongs to the technical field of medicine, and particularly relates to a peptidylarginine deiminase PAD4 inhibitor compound shown in a formula (I) or pharmaceutically acceptable salts,stereoisomers and tautomers thereof, as well as pharmaceutical compositions, pharmaceutical preparations and application thereof. X, Y, R1, R2, R3, R4, R5, R7, R8, R9, ring B and m are as defined in the specification. The compound has inhibitory effect on peptidylarginine deiminase PAD4, and can be used for treating various diseases, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, cystic fibrosis, cancer, cutaneous lupus erythematosus, asthma and psoriasis.

BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.